

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnostics Advisory Committee (DAC)

Minutes of the Meeting on Tuesday, 20 June 2017

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

PRESENT:

Standing Committee members:

Dr Mark Kroese (Chair)
Mrs Alexandria Moseley
Professor Anthony Wierzbicki
Professor Christopher Hyde
Dr Dermot Neely
Professor Enitan Carroll
Dr Jim Gray
Mr John Bagshaw
Dr Michael Messenger
Dr Owen Driskell
Mr Patrick McGinley
Dr Peter Naylor
Dr Simon Fleming
Dr Steve Edwards

Standing Committee apologies:

Professor Adrian Newland
Mr John Hitchman
Professor Mark Sculpher
Professor Matt Stevenson
Dr Simon Richards
Professor Steve Halligan
Dr Sue Crawford

NICE staff in attendance:

Mark Campbell, Associate Director, Medical Technologies Evaluation Programme
Thomas Walker, (Technical lead) Technical Analyst, DAP
Frances Nixon, Technical Adviser, DAP
Robert Fernley, Project Manager, DAP
Nick Lowe, Administrator, DAP

Observing:

Elaine Chesworth, Medical Technology Implementation Manager
Ian Mather, Business Analyst
Lydia Shears, Public Involvement Adviser

1. Introduction to the meeting

The Chair welcomed Committee members, observers and members of the public.

Apologies were noted.

2. Code of conduct for members of the public attending the meeting

The Chair explained the code of conduct to the members of the public attending this meeting.

3. Any other business

No other business was offered.

4. Minutes from the last Committee meeting

The Committee agreed the minutes from the 23 March 2017 Committee meeting.

5. NICE's advisory body guide to declaring a conflict of interest

The Chair drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

Tests in secondary care to identify people at high risk of ovarian cancer**External Assessment Group representatives: Kleijnen Systematic Reviews Ltd**

Dr Bram Ramaekers, Health Economist

Dr Marie Westwood, Review Manager

Sabine Grimm, Health Economist

Specialist Committee members:

Dr Cathie Sturgeon, Consultant Clinical Scientist

Dr Hilary Morrison, Lay Specialist Committee Member

Mr Jed Hawe, Consultant Gynaecologist

Dr Jurjees Hasan, Consultant Medical Oncologist

Dr Michael Weston, Consultants Radiologist

Professor Richard Edmondson, Professor of Gynaecological Oncology

Mr Stuart Morgan, Lay Specialist Committee Member

Dr Sudha Sundar, Senior Lecturer & Consultant in Gynaecological Oncology

Dr Tracie Miles, Clinical Nurse Specialist

Specialist Committee member apologies:

None

PART 1 AND PART 2 (open and closed parts of the meeting).**Part 1 – Open session**

The Chair welcomed representatives from Abbott Laboratories, Fujirebio Diagnostics AB, International Ovarian Tumor Analysis Group (IOTA) and Roche Diagnostics Ltd.

There were 3 public attendees.

The Chair asked Committee members to declare any relevant interests.

- Professor Mark Sculpher declared a personal specific interest; this meant he was unable to take part in the meeting.
- Simon Richards declared a personal specific financial interest; this meant he was unable to take part in the meeting.

The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of tests in secondary care to identify people at high risk of ovarian cancer.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

The Chair thanked the manufacturer representatives for their attendance, participation and contribution to the meeting.

End of Part 1**Part 2 – closed session**

Agreement on the content of the Diagnostic Consultation Document (DCD) was discussed by the committee.

End of Part 2**Date, time and venue of next meeting**

Thursday, 27 July 2017 at Mercure Manchester Piccadilly Hotel, Portland Street, Manchester, M1 4PH,